DeepMed Research

Gradalis, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Holding

Established: 2003-01-01

Employees: 11

Market Cap: -

Website: http://www.gradalisinc.com

Clinical Trials

Expanded Access of Vigil in Solid Tumors

Conditions: Solid Tumor
Ewing Sarcoma
Ewing's Tumor Metastatic
Ewing's Sarcoma Metastatic
Advanced Gynecological Cancers
Ovarian Cancer
Cervical Cancer
Uterine Cancer

First Posted Date: 2019-02-15

Last Posted Date: 2025-01-09

Lead Sponsor: Gradalis, Inc.

Registration Number: NCT03842865

Locations: 🇺🇸
Texas Oncology - Pediatrics, Dallas, Texas, United States

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

Phase 3

Terminated

Conditions: Neoplasms, Connective Tissue
Sarcoma, Ewing
Ewing Sarcoma
Ewing Family of Tumors
Ewing's Tumor Metastatic
Ewing's Sarcoma Metastatic
Ewing's Tumor Recurrent
Neoplasms, Bone Tissue
Rare Diseases
Sarcoma

Interventions: Biological: Vigil
Drug: Irinotecan
Drug: Temozolomide

First Posted Date: 2018-04-12

Last Posted Date: 2023-04-26

Lead Sponsor: Gradalis, Inc.

Target Recruit Count: 32

Registration Number: NCT03495921

Locations: 🇺🇸
Texas Oncology - Pediatrics, Dallas, Texas, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Dana-Farber/Boston Children's Cancer and Blood Disorders, Boston, Massachusetts, United States

and more 12 locations

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Phase 2

Completed

Conditions: Uterine Cancer
Ovarian Cancer
Advanced Gynecological Cancers
Cervical Cancer

Interventions: Biological: Vigil
Drug: Atezolizumab

First Posted Date: 2017-03-08

Last Posted Date: 2023-04-05

Lead Sponsor: Gradalis, Inc.

Target Recruit Count: 25

Registration Number: NCT03073525

Locations: 🇺🇸
Billings Clinic, Billings, Montana, United States
🇺🇸
Prisma Health Cancer Institute, Greenville, South Carolina, United States
🇺🇸
Dartmouth-Hitchcock Medical Center/ Norris Cotton Cancer Center, Lebanon, New Hampshire, United States

and more 3 locations

Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma

Phase 1

Completed

Conditions: Ewing's Sarcoma
Ewing's Tumor Metastatic
Ewing's Tumor Recurrent
Ewing's Sarcoma Metastatic
Rare Diseases
Ewing Family of Tumors
Sarcoma

Interventions: Biological: pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex

First Posted Date: 2016-04-13

Last Posted Date: 2023-11-13

Lead Sponsor: Gradalis, Inc.

Target Recruit Count: 7

Registration Number: NCT02736565

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Mary Crowley Cancer Research Centers, Dallas, Texas, United States

Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Metastatic Non-small Cell Lung Cancer
Advanced Non-small Cell Lung Cancer
Lung Neoplasms

Interventions: Biological: Vigil™
Drug: Nivolumab

First Posted Date: 2015-12-24

Last Posted Date: 2017-07-31

Lead Sponsor: Gradalis, Inc.

Registration Number: NCT02639234

Locations: 🇺🇸
Texas Oncology, P.A., Texas Cancer Center, Abilene, Texas, United States
🇺🇸
Mary Crowley Cancer Research Centers, Dallas, Texas, United States
🇺🇸
Cancer Care Northwest, Spokane Valley, Washington, United States

Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma

Phase 1

Completed

Conditions: Melanoma Recurrent
Malignant Melanoma
Melanoma

Interventions: Biological: Vigil
Drug: Pembrolizumab

First Posted Date: 2015-10-14

Last Posted Date: 2017-09-27

Lead Sponsor: Gradalis, Inc.

Target Recruit Count: 2

Registration Number: NCT02574533

Locations: 🇺🇸
Texas Oncology P.A., Texas Cancer Center, Abilene, Texas, United States
🇺🇸
Mary Crowley Medical Research Centers, Dallas, Texas, United States
🇺🇸
Cancer Care Northwest, Spokane, Washington, United States

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Phase 2

Completed

Conditions: Ewing's Sarcoma

Interventions: Biological: Vigil
Drug: Gemcitabine
Drug: Docetaxel
Drug: Temozolomide
Drug: Irinotecan

First Posted Date: 2015-07-29

Last Posted Date: 2022-12-22

Lead Sponsor: Gradalis, Inc.

Target Recruit Count: 22

Registration Number: NCT02511132

Locations: 🇺🇸
Mary Crowley Cancer Research Centers, Dallas, Texas, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Nicklaus Children's Hospital (Miami Children's Health System), Miami, Florida, United States

and more 3 locations

A Trial of Vigil for Participants With Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Ovarian Neoplasms
Ovarian Cancer

Interventions: Other: Placebo
Biological: Vigil

First Posted Date: 2015-01-27

Last Posted Date: 2025-01-09

Lead Sponsor: Gradalis, Inc.

Target Recruit Count: 92

Registration Number: NCT02346747

Locations: 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Mary Crowley Cancer Research Centers, Dallas, Texas, United States

and more 23 locations

Salvage Ovarian FANG™ Vaccine + Carboplatinum

Phase 2

Completed

Conditions: Stage III Ovarian Cancer
Stage IV Ovarian Cancer

Interventions: Biological: Vigil™ Vaccine
Drug: Carboplatinum
Drug: Carboplatinum and Taxol

First Posted Date: 2013-06-03

Last Posted Date: 2018-06-19

Lead Sponsor: Gradalis, Inc.

Target Recruit Count: 1

Registration Number: NCT01867086

Locations: 🇺🇸
Mary Crowley Cancer Research Centers, Dallas, Texas, United States

Salvage Ovarian FANG™ Vaccine + Bevacizumab

Phase 2

Completed

Conditions: Stage IV Ovarian Cancer
Stage III Ovarian Cancer

Interventions: Biological: Vigil™ Vaccine
Drug: Bevacizumab

First Posted Date: 2012-03-13

Last Posted Date: 2021-10-19

Lead Sponsor: Gradalis, Inc.

Target Recruit Count: 5

Registration Number: NCT01551745

Locations: 🇺🇸
Mary Crowley Cancer Research Centers, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy